Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Compare

1,656 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARCT Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Arcturus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$51.63

▲(303.67%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $51.63 with a high forecast of $66.00 and a low forecast of $32.00. The average price target represents a 303.67% change from the last price of $12.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","67":"$67","22.75":"$22.8","37.5":"$37.5","52.25":"$52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,22.75,37.5,52.25,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,16.90153846153846,20.993076923076924,25.084615384615383,29.176153846153845,33.26769230769231,37.35923076923077,41.45076923076923,45.542307692307695,49.63384615384616,53.72538461538462,57.81692307692308,61.90846153846154,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,15.796153846153846,18.782307692307693,21.768461538461537,24.754615384615384,27.74076923076923,30.72692307692308,33.713076923076926,36.69923076923077,39.68538461538462,42.67153846153847,45.657692307692315,48.643846153846155,{"y":51.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,14.286153846153846,15.762307692307692,17.23846153846154,18.714615384615385,20.19076923076923,21.666923076923077,23.143076923076922,24.619230769230768,26.095384615384614,27.57153846153846,29.04769230769231,30.52384615384615,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.66,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$66.00

Average Price Target$51.63

Lowest Price Target$32.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

1.64%

Upside

Reiterated

06/07/25

Arcturus Therapeutics' overall stock score reflects its strong gross margins and strategic focus on mRNA therapeutics, offset by financial challenges such as consistent net losses and declining revenues. Technical analysis provides moderate support, while valuation remains a concern due to the negative P/E ratio.

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/05/25

Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating

Greg HarrisonScotiabank

Scotiabank

$32

Buy

150.20%

Upside

Initiated

05/28/25

Arcturus Therapeutics initiated with an Outperform at ScotiabankArcturus Therapeutics initiated with an Outperform at Scotiabank

Yanan ZhuWells Fargo

Wells Fargo

$50→$45

Buy

251.84%

Upside

Reiterated

05/14/25

Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating

Whitney IjemCanaccord Genuity

Canaccord Genuity

$68→$66

Buy

416.03%

Upside

Reiterated

05/13/25

Arcturus Therapeutics price target lowered to $66 from $68 at CanaccordArcturus Therapeutics price target lowered to $66 from $68 at Canaccord

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Arcturus Therapeutics (ARCT)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).

Yigal NochomovitzCiti

Citi

$44

Buy

244.02%

Upside

Reiterated

05/12/25

Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside

Lili (Aurélie) NsongoLeerink Partners

Leerink Partners

$63

Buy

392.57%

Upside

Reiterated

05/12/25

Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics

Ed ArceH.C. Wainwright

H.C. Wainwright

$60

Buy

369.12%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Seamus FernandezGuggenheim

Guggenheim

$71→$45

Buy

251.84%

Upside

Reiterated

04/10/25

Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim

Thomas ShraderBTIG

BTIG

$57→$58

Buy

353.48%

Upside

Reiterated

03/27/25

Arcturus Therapeutics (ARCT) PT Raised to $58 at BTIGBTIG analyst Thomas Shrader raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $58.00 (from $57.00) while maintaining a Buy rating.

Yasmeen RahimiPiper Sandler

Piper Sandler

$140

Buy

994.61%

Upside

Reiterated

03/07/25

Piper Sandler Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)

Yale JenLaidlaw

Laidlaw

$79

Buy

517.67%

Upside

Reiterated

07/02/24

Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).

Stephen BrozakWBB Securities

WBB Securities

$25

Buy

95.47%

Upside

Upgraded

06/30/24

We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

1.64%

Upside

Reiterated

06/07/25

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/05/25

Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating

Greg HarrisonScotiabank

Scotiabank

$32

Buy

150.20%

Upside

Initiated

05/28/25

Arcturus Therapeutics initiated with an Outperform at ScotiabankArcturus Therapeutics initiated with an Outperform at Scotiabank

Yanan ZhuWells Fargo

Wells Fargo

$50→$45

Buy

251.84%

Upside

Reiterated

05/14/25

Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating

Whitney IjemCanaccord Genuity

Canaccord Genuity

$68→$66

Buy

416.03%

Upside

Reiterated

05/13/25

Arcturus Therapeutics price target lowered to $66 from $68 at CanaccordArcturus Therapeutics price target lowered to $66 from $68 at Canaccord

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Arcturus Therapeutics (ARCT)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ: ARCT).

Yigal NochomovitzCiti

Citi

$44

Buy

244.02%

Upside

Reiterated

05/12/25

Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside

Lili (Aurélie) NsongoLeerink Partners

Leerink Partners

$63

Buy

392.57%

Upside

Reiterated

05/12/25

Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics

Ed ArceH.C. Wainwright

H.C. Wainwright

$60

Buy

369.12%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Seamus FernandezGuggenheim

Guggenheim

$71→$45

Buy

251.84%

Upside

Reiterated

04/10/25

Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim

Thomas ShraderBTIG

BTIG

$57→$58

Buy

353.48%

Upside

Reiterated

03/27/25

Yasmeen RahimiPiper Sandler

Piper Sandler

$140

Buy

994.61%

Upside

Reiterated

03/07/25

Piper Sandler Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)

Yale JenLaidlaw

Laidlaw

$79

Buy

517.67%

Upside

Reiterated

07/02/24

Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).

Stephen BrozakWBB Securities

WBB Securities

$25

Buy

95.47%

Upside

Upgraded

06/30/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

1 Month

xxx

Success Rate

7/10 ratings generated profit

Average Return

-4.21%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of -4.21% per trade.

3 Months

xxx

Success Rate

4/10 ratings generated profit

Average Return

-5.72%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -5.72% per trade.

1 Year

Lili (Aurélie) NsongoLeerink Partners

Success Rate

2/10 ratings generated profit

Average Return

-20.51%

reiterated a buy rating 29 days ago

Copying Lili (Aurélie) Nsongo's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -20.51% per trade.

2 Years

xxx

Success Rate

4/18 ratings generated profit

Average Return

-27.58%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -27.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARCT has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 51.63.

Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$0.94 with a range of -$1.76 to -$0.49. The previous quarter’s EPS was -$0.52. ARCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $18.68M with a range of $0.00 to $29.70M. The previous quarter’s sales results were $25.48M. ARCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 51.63.

What is ARCT’s upside potential, based on the analysts’ average price target?

Arcturus Therapeutics has 303.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARCT a Buy, Sell or Hold?

Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Arcturus Therapeutics’s price target?

The average price target for Arcturus Therapeutics is 51.63. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $66.00 ,the lowest forecast is $32.00. The average price target represents 303.67% Increase from the current price of $12.79.

What do analysts say about Arcturus Therapeutics?

Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ARCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

ARCT Analyst Ratings

ARCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcturus Therapeutics

ARCT Analyst Recommendation Trends

ARCT Financial Forecast

ARCT Earnings Forecast

ARCT Sales Forecast

ARCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts